Ann: Appendix 4D & Half-Year Financial Statements, page-83

First 83 Last

Share
Profile

Follow
Sector

35,472 Posts.

2863

09/03/23

22:55

Post #: 66688126
Share

Originally posted by benelong: ↑

It is very possible that the impressive Cymerus technology could greatly improve the economical and efficient production of beneficial stem cell treatments. But if I understand the situation correctly it would not just be a simple matter of MSB plonking a new manufacturing process on top of its very advanced and increasingly impressive phase 3 trials.
I suspect they would have to go back to square one and convince the FDA of safety, efficacy and mode of action of a quite different product. The fact that they are relatives in the stem cell "family" does not give the idea a head start.
The safety issue alone would require trials over some years and with vastly more subjects than the few that CYP has tested. MSB is too close to victory to consider that.
It's a fair hope that some outfit might rescue CYP but it won't be MSB. The big pharma boys appear to want to join the party a very long way towards a successful conclusion. The support of experts such as Prof Hunter and others is reassuring to SH but it's got no value to TO prospects. They need years of safety, proof of efficacy and documented science before they'll be interested. That takes hundreds of millions of dollars quite apart from successful trials. Where will the money come from?

Expand

Bene long wrong wrong
Go back to sleep old boy, you've been schooled for years for your lack of knowledge and misinformation.

CYP Price at posting: 28.5¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

SRL

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

BOE

Boss extends June win streak with boosted Alta Mesa extraction rates

First 83 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 16.0¢		Change 0.005(3.23%)		Mkt cap ! $36.15M

Open	High	Low	Value	Volume
15.5¢	16.0¢	15.5¢	$4.604K	29.61K

Buyers (Bids)

No.	Vol.	Price($)
5	58900	15.5¢

Sellers (Offers)

Price($)	Vol.	No.
16.0¢	15860	3

View Market Depth

No.	Vol.	Price($)
5	58900	0.155
6	186866	0.150
1	5000	0.145
2	45000	0.140
2	110937	0.130

Price($)	Vol.	No.
0.160	15860	3
0.165	60867	3
0.170	70193	3
0.175	64838	3
0.180	62619	3

Last trade - 10.37am 27/06/2025 (20 minute delay)

CYP (ASX) Chart

Ann: Appendix 4D & Half-Year Financial Statements, page-83

Australia’s gas crisis is here – and dying coal plants aren’t helping

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

Boss extends June win streak with boosted Alta Mesa extraction rates

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Appendix 4D & Half-Year Financial Statements, page-83

Top Stories

Australia’s gas crisis is here – and dying coal plants aren’t helping

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

ASX Market Open: IPO hype, Wall Street ATHs push Aussies into green hope | June 27

Boss extends June win streak with boosted Alta Mesa extraction rates

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News